Immunotherapy for COVID-19: Evolving Treatment of Viral Infection and Associated Adverse Immunological Reactions

This review on COVID-19 vaccinotherapy enables a comparative analysis of the short-list of currently approved major vaccines. These include the Pfizer and Moderna first mRNA vaccines under FDA purview and the Oxford/AstraZeneca simian adenovirus-vectored vaccine (under UK-MHPRA guidance), all produced in record time, being safe and effective. The Pfizer and Moderna double dose vaccines have the clear edge in treatment efficacy, being in the 90% range compared to AstraZeneca in the average 70%. However, the AZ double dose vaccine has significant advantages with respect to lower cost and stability in storage.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research